Drug-specific variables that may affect half-life Drug formulation (ie, modified or controlled release preparations extend half-life) How the drug behaves in the body (ie, zero-order, first-order, or multi-compartmental pharmacokinetics) How the drug is administered (half-life may be different with IV administration, compared to intranasal or oral administration) How the drug is cleared from the body (eg, kidneys, liver, lungs) If the drug accumulates in fat or other types of tissue If the drug binds to proteins or not Presence of metabolites or other drugs that may interact Properties of the drug, including molecule size, charge, and pKa The volume of distribution of a drug Other variables, such as if the drug is actively transported, is self-induced, or has saturation pharmacokinetics

Sources and Further Reading NICE NG238 Obesity: identification, assessment and management (2024): NICE TA875 Semaglutide for managing overweight and obesity (2023): Electronic Medicines Compendium (eMC) SmPC for oral semaglutide: MHRA Regulatory status of semaglutide: NHS Weight Management: British National Formulary (BNF):
However, there is conflicting epidemiological evidence on statins and PD risk [143]
1 Everything is bundled into a single monthly fee: medication, delivery, coaching, app access, and peer support
doi:10.1111/ijd.13585
Clinical evidence shows sustained benefit over 2+ years with ongoing therapy